© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Kestra Medical Technologies, Ltd. (KMTS) stock declined over -1.38%, trading at $22.83 on NASDAQ, down from the previous close of $23.15. The stock opened at $23.38, fluctuating between $22.11 and $24.07 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jul 31, 2026 | 23.38 | 24.07 | 22.11 | 22.83 | 277.95K |
| Jul 30, 2026 | 22.91 | 24.00 | 22.22 | 23.15 | 283.75K |
| Jul 29, 2026 | 23.66 | 24.06 | 22.66 | 22.75 | 316.04K |
| Jul 28, 2026 | 22.99 | 24.24 | 22.58 | 23.86 | 451.35K |
| Jul 27, 2026 | 21.50 | 23.06 | 21.50 | 22.82 | 195.81K |
| Jul 24, 2026 | 21.90 | 21.92 | 20.89 | 21.06 | 176.38K |
| Jul 23, 2026 | 20.43 | 21.57 | 20.40 | 21.57 | 214.17K |
| Jul 22, 2026 | 21.89 | 22.34 | 20.89 | 20.89 | 424.93K |
| Jul 21, 2026 | 22.51 | 23.13 | 22.06 | 22.24 | 303.1K |
| Jul 20, 2026 | 24.29 | 24.68 | 23.14 | 23.24 | 428.06K |
| Jul 17, 2026 | 23.64 | 24.54 | 23.07 | 24.42 | 339.76K |
| Jul 16, 2026 | 24.31 | 26.52 | 23.68 | 23.98 | 554.73K |
| Jul 15, 2026 | 24.10 | 24.80 | 21.03 | 24.62 | 842.36K |
| Jul 14, 2026 | 24.34 | 24.68 | 23.56 | 24.18 | 431.95K |
| Jul 13, 2026 | 25.69 | 26.33 | 24.65 | 24.76 | 334.48K |
| Jul 10, 2026 | 26.29 | 26.62 | 25.26 | 25.99 | 454.39K |
| Jul 09, 2026 | 26.40 | 27.00 | 26.18 | 26.69 | 386.91K |
| Jul 08, 2026 | 27.27 | 27.65 | 26.50 | 26.80 | 694.83K |
| Jul 07, 2026 | 28.22 | 28.81 | 27.42 | 27.85 | 404.31K |
| Jul 06, 2026 | 26.98 | 27.98 | 25.99 | 27.88 | 580.88K |
Kestra Medical Technologies, Ltd. operates at the intersection of wearable medical technology and digital healthcare. Its core mission is to revolutionize patient outcomes in cardiovascular disease through intelligent, intuitive, and connected monitoring and therapeutic intervention solutions. The company's flagship offering is the Cardiac Recovery System (CRS) platform, which it develops and commercializes. This unified solution seamlessly integrates cardiac monitoring, therapeutic treatment, digital health capabilities, and patient support services. A central component of the CRS is the ASSURE WCD, a wearable cardioverter defibrillator specifically engineered to protect individuals at elevated risk of sudden cardiac arrest (SCA). Beyond its hardware, the CRS platform also encompasses a suite of integrated digital solutions and services. These are designed to foster enhanced engagement and oversight between patients and healthcare providers, ultimately striving for improved patient well-being. Founded in 2014, the company is headquartered in Kirkland, Washington.
| Employees | 330 |
| Beta | 0.47 |
| Sales or Revenue | $95.13M |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | April |
| Sector | Healthcare |
| Industry | Medical - Instruments & Supplies |